PLYX - Polaryx Therapeutics Inc Common Stock Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 1.88 USD StockBonds Safety Grade: Altman Z-Score (Bankruptcy Risk): 52.70 StockBond Score: -2.84 Company Description Polaryx Therapeutics Inc functions as a biotechnology firm dedicated to advancing smallmolecule therapies for lysosomal storage and neurodegenerative conditions Its developmental pipeline includes a trio of promising candidates PLX100 which combines PLX200 with an ancillary supplement targeting late infantile neuronal ceroid lipofuscinosis LINCL and related forms of NCL PLX200 a repurposed compound already utilized to address various diseases in both adult and pediatric populations And PLX300 derived from an edible plant which works by activating PPARa to enhance the production of transcription factor EB The company established in 2014 maintains its base of operations in Paramus New Jersey